Clinical Trial Update: Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment [Phase 2]

View source ↗

Summary

Phase 2 trial investigating carfilzomib in metastatic castration-resistant prostate cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Carfilzomib (carfilzomib)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-12-19